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1. Introduction 
Therapy in nuclear medicine practice has a long distinguished history. Nuclear medicine 
therapy is required to be highly specific and targeted, since it always involves 
administration of unsealed sources of radioactivity. Most therapy agents utilize ß-particle 
emissions for their ability to penetrate tissues. This deposition of energy in tissue by ß 
emitters results in cellular damage. Among the ß emitters there are several choices with 
respect to energy of the ß emission. Lower energy ß particles can travel a few cell diameters, 
or at most in the sub-millimeter range. Higher energy ß particles such as those emitted by Y-
90 have an excellent tissue penetration with a range beyond the source of several 
millimeters. The physical half-life of the therapeutic radionuclide is an important 
consideration and underlying principle for therapy planning. Rarely, except in thyroid 
treatment, is the simple salt form of the radionuclide used. It is most likely attached to a 
drug or particle that controls its biodistribution. The ideal therapeutic radiopharmaceutical 
is one that remains attached to the parent drug or its metabolites, and is excreted rapidly 
through a known simple route1.  
For selected patients with HCC, confined to the liver but not amenable to resection or 
transplantation, both systemic and locoregional therapies can be considered. These include  
1. Percutaneous interventions (ethanol injection, radiofrequency thermal ablation),  
2. Transarterial interventions  
a. Embolization (TAE), chemoperfusion (TAC), or chemoembolization (TACE),  
b. Radioembolization (RE) or radioactive agent perfusion such as 131Iodine-Lipiodol or 
188RE-Lipiodol  
3.  External radiation therapy and  
4.  Chemotherapy, including gene and immune therapy.  
In this chapter we focus only on the therapeutic indications, usefulness and methods of 
treatment with 131-Iodine Lipiodol (131I-Lipiodol). Its rationale comes from the anatomical 
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and physiological aspects of HCC being exploited for the delivery of the therapeutic agent. 
The liver has a dual blood supply: the hepatic artery and the portal vein. Observations on 
vascular supply to hepatic malignancies have demonstrated that metastatic hepatic tumours 
>3 mm derive in contrast to healthy hepatic cells 80–100% of their blood supply from the 
arterial rather than the portal hepatic circulation2.  
2. Basic characteristics of 131 I-Lipiodol  
131I is a beta emitting radionuclide with a physical half life of 8.04 days. The maximum and 
mean beta particle energies are 0.61MeV and 0.192MeV respectively. Additionally, 131I 
emits a principal gamma photon of 364 keV (81% abundance). The Beta radiation of I131 is 
responsible for its therapeutic effects while gamma radiation makes the distribution of the 
radiopharmaceutical visible. 
Lipiodol is a mixture of iodized esters of poppy seed oil fatty acids used as a contrast 
medium for the detection of HCC which remains in these tumours for a longer period 
compared to normal liver or in other tissues. Isotopic exchange is used to label iodine-rich 
Lipiodol with 131I (Lipiocis®, CIS Bio International/ member of IBA group). Lipiocis® is 
licensed in France for the treatment of patients with HCC and portal vein thrombosis 
(PVT)3. It was developed in the 1990s and was the first radiolabeled vector to be used in this 
setting. According to biodistribution data, more than 75% of the 131I-Lipiodol stays 
following the arterial administration in the liver and the remainder reaches the lungs4. Other 
tissues, including the thyroid gland, receive very little radiation.  
An in vitro assessment 5 showed an unspecific uptake of Lipiodol in non-malignant 
endothelial cells apart from its concentration in cancer cell lines. Lipiodol alone does not 
appear to have any cytotoxic effect against any of the studied cell lines. However, 131I-
Lipiodol is highly and only selectively cytotoxic for the cancer cell lines. Inability of 
tumourous cells unlike non-malignant ones to expel Lipiodol, revealed by quantification 
methods using computer-assisted image analysis, may further enhance the cytotoxic effect 
of 131I-Lipiodol in cancer cells. There is no separation of the 131I from Lipiodol during the 
uptake process by the cancer cells, as Lipiodol is a naturally iodinated oil compound with an 
iodine content of 38–40%. 131I-Lipiodol shows cytotoxic effects against the cancer cell lines 
even in doses as small as a quarter of the radioactivity of the 131I alone5. 
The tumour/ non tumour uptake ratio is about 15–20:1 and increases with time, while the 
effective half life within the HCC tissue is also longer than that in healthy tissues (almost 6 
days versus 4 days). Generally, more than 10 % of the injected Lipiodol remains within the 
tumour 6. The retention of 131I-Lipiodol in HCC tumours after intra-arterial infusion is 
related not only to embolization in the micro vessels of the tumour, but also to the entry into 
the interstitium and the tumour cells themselves. This retention can be assessed by 
tomodensitometric examination and inversely relates to the tumour size. Indeed, 88% of the 
HCCs smaller than 5 cm exhibit a high retention (of type 3 or 4 according to the criteria of 
Maki et al.7) whereas 74% of the HCCs larger than 10 cm exhibit only a weak retention of 
less than 50% (of type 1 or 2 according to the criteria of Maki) 8, 9. Moreover, the clearance of 
Lipiodol from the tumour lasts longer than from the normal liver or from the lungs, possibly 
because of a lack of macrophagic cells in the tumour 3. 131I-Lipiodol is eliminated mainly 
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through the urinary tract, reaching 30–50% of the injected activity at day 8, but also to a 
small extent by way of the faeces (<3% at day 5) 4. 
The required therapy activity for the intended tumour dose can be calculated for a given 
tumour mass according to its size. For instance producing 120 Gy in a tumour with a 
diameter of 1 cm requires less than 3 MBq I-131 while the same dose in a tumour with a 
fivefold larger diameter requires hundredfold more activity 10. 
The radionuclide is supplied in 2 ml solution for injection and stored in a 4 ml cone shaped 
glass vial. The specific activity at calibration date is 1.1 GBq/ml and its shelf life from this 
time is 3 days 11, 12. 
The conjunction of lipiodol with TACE, also called TOCA (transarterial oily 
chemoembolization), has also been used allowing the delivery of locally concentrated 
therapy due to the selective retention of the agent in the tumours for an extended period 13. 
3. Basics of interventional nuclear medicine therapies of HCC with I131-
Lipiodol 
Radiation is tumoricidal if sufficient doses can be delivered selectively to the tumour without 
damaging adjacent normal tissue 14. Normal hepatocytes have a lower tolerance to the effects 
of radiation than neoplastic tissue. The dose required to destroy solid tumors, estimated at ≥70 
Gy, is far greater than the liver tolerance dose of 35 Gy when delivered to the whole liver in 1.8 
Gy/d fractions 15. If the whole liver is exposed to external-beam radiation at a mean radiation 
dose of 43 Gy, more than 50% of patients develop liver dysfunction 16. Conformal and 
stereotactic radiation therapy techniques can be used to deliver much higher radiation doses in 
cases with focal involvement 17; however, since primary neoplasms are often multifocal and 
irregular in shape and potentially replace large parts of the liver volume, only a small minority 
of patients are optimal candidates for such therapies 18. Internal radiation aims at improving 
the selectivity of the radiation by targeting the radioisotopes to the tumour cells. To achieve 
this targeting, the therapeutic radiopharmaceuticals such as 90Y microspheres or 131I-Lipiodol 
may be administered via the hepatic artery 19. 
Based on studies considering biodistribution of intraarterial 131I-Lipiodol in humans 4, 20, 21, 
radiation doses for every mCi (37 MBq) of administered activity were estimated to be 31 cGy 
for the normal liver, 22 cGy for the lungs, and 239 cGy for a tumor with a greatest diameter 
of 4 cm using the formula:  
 Dose (cGy) = 0 073.8 0.0346
A A
E Te g
M M
        
where E is the average beta energy (MeV), Te is the effective half-life (days),   is the specific 
gamma ray constant (cGy cm2/mCi hr), Ao is the initial activity (µCi), M is the mass(g), and 
g is the geometric factor (cm). 
4. Contraindications 
Absolute contraindications 
1. Pregnancy and breastfeeding, 2. life expectancy less than 1 month, 3. hepatic 
encephalopathy, 4. tumour Stage OKUDA III11, 12. 
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Relative contraindications 
1. High extrahepatic tumor burden, 2. acute or severe chronic pulmonary disease, 3. The 
presence of contraindications for hepatic artery catheterisation 11, 12.  
5. Therapeutic indications for 131I-Lipiodol 
5.1 Palliative treatment of inoperable hepatocellular carcinoma  
An improved survival rate is readily documented for those treated with 131I-Lipiodol, 
comparing to those receiving only medical support 22. The treatment is more effective for 
small, solitary and well encapsulated tumors and the response rate decreases with 
increasing tumor size. Its main limitation is its ineffectiveness in large (>5 cm) tumours. 
However, transarterial therapy with 131I-Lipiodol is superior to systemic therapy in 
tumours up to 5 cm in diameter23. 
The data on therapy efficacy have remained non-uniform. A decrease in tumour size has 
been reported in about 50 % to 60 % of patients; two early studies with seven and nine 
patients showed response in all tumours 24, 25. In larger studies classifying therapy success 
according to the WHO criteria, the response rate decreases to about 30 % 26. This is in 
agreement with our own data 27. Reported response rates in different studies are 
summarised in table 1; only reports with more than ten patients, data on changes in tumour 
size and follow-up studies of at least one month, are considered.  
 
First author, 
year, reference 
Number of 
evaluable 
patients 
CR PR MR SD 
 
 
 
PD AFP decrease 
Yoo 199129 24 0 3 5 8 8 13/16 
Raoul 199230 30 0 18 4 6 2 22/29 
Leung 199431 22 1 3 - 12 6 13/25 
Bhattacharya 
199532 
22 0 7 - 8 7 2/22 
Raoul 199728 25 1 15 4 3 2 20/40 
De Baere 
199926 
23 0 3 - 12 8 - 
Risse 2000 27 13 0 2 3 4 4 - 
Rindani 2002 33 12 0 6 - 5 1 5/7 
Borbath 2005 34 19 1 0 - 7 11 2/24 
Risse 2006 35  17 0 4 1 7 5 - 
Boucher 200736 40 1 18 - 19 2  
CR: complete response, PR: partial response (tumour reduction > 50 %), MR: minimal response (tumor 
reduction between 25 an 50 %, AFP alpha-fetoprotein, SD: stable disease (tumour size change between -
25 % - +25 %), PD: progressive disease ( tumour increase > 25 %) 
Table 1. Efficacy of 131I-Lipiodol therapy in patients with unresectable HCC 
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131I-Lipiodol is also comparatively favourable to other regional therapy procedures for 
palliative treatment of HCC. A multicentre randomised trial by Raoul et al28 showed that 
131I-Lipiodol therapy (n=73) was associated with a better patient tolerance and fewer 
vascular complications than TACE (n=69), although no survival advantage was 
demonstrated28.  
In a published study from our group 38 courses of intra-arterial 131I-Lipiodol therapy with 
a total activity up to 6.7 GBq were performed in 18 patients with HCC (6 with PVT)35. 
Tumour volume decreased in 20/32 index nodules (63%) after the first course. Repeated 
therapy frequently resulted in further tumour reduction. Partial response was seen in 11 
nodules while 4 nodules showed a minor response. Stable disease was found in 12 patients 
and progressive disease in 5. Significant response was associated with pre-therapeutic 
nodule volume up to 150 ml (diameter of 6.6 cm). Survival rate after 3, 6, 9, 12, 24 and 36 
months was 78, 61, 50, 39, 17, and 6% respectively. Matched-pairs analysis of survival 
revealed 131I-Lipiodol to be superior to medical treatment. The most important side effect 
was a pancreatitis-like syndrome while overall tolerance was very acceptable. 
The median survival in patients with unresctable HCC undergoing 131I-Lipiodol therapy 
has been reported between 7 and 27 months 34, 36-38. Chua et al reported the factors 
associated with survival in a newly published study including the AJCC stage (1-2 vs 3-4), 
Barcelona Clinic Liver Cancer stage (A-B vs C), Cancer of the Liver Italian Program score (< 
2 vs >2), maximum tumor size (<4 vs >4 cm), extrahepatic disease, previous surgery and 
response to treatment (favorable vs unfavourable).38 Considering response rate, AJCC stage 
1-2 and Cancer of the Liver Italian Program score < 2 were found to be independent 
predictors for a favorable response in this study38. 
5.1.1 Palliative treatment of HCC with Portal vein thrombosis (PVT) 
Although the PVT prohibits any attempt of TACE, 131I-Lipiodol has proved to be an 
effective therapy option in patients with HCC and PVT39. Raoul et al. compared 131I-
Lipiodol therapy and best supportive care in patients with HCC and PVT. The survival rates 
at 3, 6 and 9 mo was 71%, 48% and 7% for the treated group; and 10%, 0% and 0% for the 
group receiving only supportive care. The authors concluded that 131I-Lipiodol is a safe and 
effective palliative treatment of HCC in the presence of portal vein thrombosis 22. However 
it should be noted that radioembolization (RE) with 90Y-Microspheres has proved to be a 
feasible alternative treatment for HCC patients with PVT as discussed in following section.  
5.1.2 131I-Lipiodol versus radioembolisation with 90Y-Microspheres 
90Y radioembolization (RE), or selective internal radiation therapy (SIRT), is a promising 
catheter-based liver-directed modality approved by the Food and Drug Administration for 
patients with primary and metastatic liver cancer40. In a meta-analysis of 14 published 
articles Venti et al showed almost 80% any response (AR = [CR +PR +SD]) for a total of 325 
patients with HCC. According to this meta-analysis, treatment with resin microspheres was 
associated with a significantly higher proportion of AR than with glass microsphere (0.89 vs 
0.78 [P <0.02])41.  
Although RE is currently the preferred method for treating HCC compared to 131I-Lipiodol, 
its embolic nature makes severe liver dysfunction a theoretic contraindication for this 
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technique, as in TACE. In addition, techniques using 90Y-labeled products tend to cost up to 
10 times more than therapy with 131I-Lipiodol 42, affecting the therapeutic approach 
especially in the countries with a poor insurance system.  
PVT is not an absolute contraindication for RE any more. Although resin microspheres 
could pose the patient at risk for significant liver dysfunction based on the embolic 
treatment effect, therasphere has been shown to be safe even when the portal vein has been 
invaded by tumor14. However, recent studies describe safe performance of RE with resin 
microspheres even in PVT. There is no prospective study which compares these two 
methods (RE vs 131I-Lipiodol) in patients with PVT in HCC considering response rate, time-
to-progression, and survival. 
5.1.3 131I-Lipiodol-therapy versus TAE and TACE  
131I-Lipiodol therapy in patients with cirrhosis and HCC has an efficacy similar to that of 
TACE/TAE therapy 28, 32, 42. However 131I-Lipiodol appears to be of more benefit in patients 
with advanced disease, for example, in those with Okuda stage III disease or BCLC stage D 
as well as in patients with PVT 42. PVT patients receiving 131I-Lipiodol lived on average 
almost a year longer than those treated with TACE or TAE. Moreover, 131I-Lipiodol is much 
better tolerated than chemoembolization, both in terms of clinically expressed side effects 
and arteriographic findings 28. 
5.2 Performing 131I-Lipiodol as an adjuvant or neo-adjuvant therapy  
Early intrahepatic recurrence is common after curative resection of hepatocellular 
carcinoma, frequently due to microscopic metastatic disease or less commonly, 
metachronous multicentric carcinoma within the liver remnant not detected before or 
during resection by conventional imaging 43 and has led to attempts at adjuvant or 
neoadjuvant therapies.  
5.2.1 131I-Lipiodol as an adjuvant therapy  
It has been thought that when the postsurgical liver starts to regenerate, small microscopic 
daughter tumours can be stimulated to grow. If these were pre-cleared the chances of a 
recurrence would be lowered. Thus,131I-Lipiodol has been used in an adjuvant setting after 
curative surgical resection 44. A single dose of 1.85 GBq 131I-Lipiodol administered 6 weeks 
after curative resection of hepatocellular carcinoma could significantly decrease the rate of 
recurrence and increased disease-free and overall survival in a study by Lau et al. 43. In their 
recent published paper the same authors confirmed their results after a longer follow up 45. 
These findings were also confirmed by Boucher et al. administering 2.4 GBq 131I-Lipiodol 8-
12 weeks after surgery 46. NG et. al.47 also reported a good overall survival with 1.7 GBq 
I131-Lipiodol 1-8 months after surgery. It seems that there is no clinically significant adverse 
effect of adjuvant therapy by intra-arterial131I-Lipiodol after curative liver resection for 
HCC 48. These results were also confirmed in a recent published study from Chua et. al. 49. It 
is necessary to perform more randomized controlled trials with more patients to confirm the 
role of 131I-Lipiodol as an adjuvant treatment especially considering the timing and the 
administered dose.  
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5.2.2 Neo-adjuvant 131I-Lipiodol administration before liver transplantation/resection 
In a study by Raoul et. al50 curative resection of hepatocellular carcinoma or liver 
transplantation was preceded by 2 injections of 2.4 GBq 131I-Lipiodol (5 weeks 
preoperative) to reduce intrahepatic recurrence. The procedure was well tolerated and 
associated with an objective tumour response in 56 % and a complete histological response 
in 24 % of 34 treated patients. An objective tumour response or necrosis of more than 90 % 
of the tumour mass was observed in three-quarters of these patients. Brans et. al. treated 10 
HCC patients with almost 1.8 GBq 131I-Lipiodol in a pilot study followed by liver 
transplantation within 1–9 months 51. The evidence of an anti-tumoural effect of 131L-
Lipiodol was observed in 50% of patients. However, performing randomized comparisons 
between surgery alone versus surgery after intra-arterial injection of 131I-labelled Lipiodol in 
patients with large but technically resectable tumours is needed. 
6. Imaging before performing the therapy 
The work-up includes a three-phase contrast computed tomography (CT) and gadolinium-
enhanced magnetic resonance imaging (MRI) of the liver for the assessment of tumour and 
non-tumour volume, portal vein patency, and the extent of extra-hepatic disease. Although 
FDG-PET is suitable for tumours showing high glucose metabolism such as colorectal 
carcinoma, melanoma, head and neck, and breast cancers, malignancies such as HCC or 
neuroendocrine tumours, except for their aggressive types show no or a very low-grade 
FDG uptake40. 
The suboptimal sensitivity of FDG-PET for the detection of HCC, ranging between 50% and 
70% makes it an unsatisfactory imaging choice for the pre- and post-treatment evaluation in 
this group of patients; however, it adds valuable prognostic information (metabolic grading) 
as patients with a negative FDG-PET show a better prognosis than those with high FDG 
uptake. Choline PET/CT may also play a role in imaging of specific types of HCC in the 
near future 40, 52-54.  
7. Intervention technique  
Treatment with 131I-Lipiodol serves as an example for multidisciplinary management 
including the patient selection and care, the detailed anatomical study and dose calculation, 
the post-interventional treatment including timing and selection of systemic treatment, 
adequate follow-up of the patient as well as the management of possible complications. 
Prior to the therapy, patients should receive both written and verbal information about the 
procedure and the palliative nature of the treatment 12. The renal functional status should be 
adequate for the use of contrast agents during the pre-therapeutic angiogram. 
Haemodialysis patients may be treated with 131I-Lipiodol, however, dialysis has to be 
planned and timed before and after the intervention. Patients should be given a peri-
interventional drug regimen with slow intravenous infusion of 24 mg dexamethasone and 8 
mg ondansetrone during the whole procedure and intraarterial injection of 50 mg pethidine 
immediately before application of the radiopharmaceutical. After blocking the thyroid with 
perchlorate, diagnostic angiography of the liver vessels should be performed with special 
attention to collateral arteries to other organs. Occasionally, computed tomography with 
arterioportography (CT-AP) via the catheter could be added, partly with the injection of 
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small amounts of “cold” Lipiodol (Guerbet®). In patients with “normal” hepatic arterial 
anatomy the catheter can be positioned in the main hepatic artery for nonselective injection 
of 131I-Lipiodol. In cases with multiple nodules or variable arterial blood supply, the liver 
lobe containing the largest tumour mass is treated in the first session and the remaining 
masses in the following ones.  
 
Fig. 1. Quantitative whole body scintigraphy obtained 7 days post therapeutic in a 52-year-
old man showing significant activity in the HCCs and only a faint lung uptake. 
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131I-Lipiodol (2.22 GBq in 2 ml / ampulla) should be prepared in an appropriately 
ventilated cabinet in the department of Nuclear Medicine to avoid radioiodine aerosol 
inhalation. Injection should take at least some minutes to ensure good tolerance by the 
patient. The procedure and special radiation protection measures have been readily 
published in detail 55. The applied activity should be determined as the difference between 
activity in the last receptacle before injection and the remaining activity of last receptacle 
and the catheter-system after flushing with saline. After the procedure the patients are 
transferred to the station and isolated until radiation exposure to their environment 
becomes low enough to be discharged (e.g in Germany < 1mSv/year) 35.  
Dexamethasone and tamoxifen could increase the tumoral uptake of Lipiodol and could be 
combined with 131I-Lipiodol to improve the therapy effectiveness 56. 
 
Fig. 2. SPECT/CT of the liver could be used for a better quantification of the radioactive 
distribution as well as dosimetry simultaneously. Note the distribution of 131I-Lipiodol in 
the HCCs showed with arrow.  
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For certain patients, in particular those presenting with a relatively large tumour several 
injections in 2-3 months interval may be necessary to obtain an effective response. 
As Garin et. al. stated, nuclear medicine specialist receives an average dose between 140 and 
443 µSv at the level of the fingers(according to the fingers) and about 17 µSv at the thorax. 
For the radiologists, the average doses received are 215 µSv and 15 µSv at the level of the 
fingers and at the thorax respectively. The authors showed that the administration of high 
therapeutic activities of 131I-Lipiodol can be carried out with a dose much lower than the 
European regulatory limit of 500 mSv at the level of the fingers for the exposed personnel 57.  
8. Follow-up 
Definitions of the appropriate length of the follow-up and the time points required for 
technical success are not well established and post treatment follow-up schedules vary 
depending on the treatment plan of each patient. For the evaluation of response, abdominal 
imaging should be performed 4 weeks and 2-3 months after each therapy 12. Follow-up 
should be performed with the same modality used pre-therapeutic such as MRI, 3 phase CT, 
18F-FDG, 11C-/18F-Cholin or 11C-/18F-Acetate PET/CT. AFP should be tested for patients 
with initially increased AFP.  
9. Dosimetry  
Becker et al. performed a dosimetric evaluation using SPECT/CT 58, applied to a series of 41 
patients who received one or more injections of 131I-Lipiodol for treatment of HCC using a 
standard activity of 2220 MBq. They found a mean tumoural absorbed dose of 248±176 Gy 
for the first treatment, compared with 152±122 Gy for the second treatment, and pointed out 
a correlation between the tumoural absorbed dose, calculated in tomographic mode, and 
morphological response to first treatment alone. These results pleaded in favour of 
increasing the administered activity at the first treatment. A tumoral absorbed dose of 280 
Gy was found to represent an effective threshold absorbed dose. While 84% of the patients 
above this value were responders, no one appeared to respond at lower absorbed doses 58. 
Tumour response adversely correlates with tumour size. High response rates have been 
found in tumour nodes with diameters below 6 cm in which an absorbed dose of up to 288 
Gy has been calculated 25, 30, 59. However, it must be considered that a reduction in tumour 
mass does not necessarily correlate with improved survival6. 
10. Safety of 131I-Lipiodol therapy  
A phase I study 24 and a multi centric phase II trial 30 could not demonstrate any specific 
toxic effects of 131I-Lipiodol. The main limiting factor was the long patient isolation 
required for the purpose of radioprotection. Consequently, a fixed injected activity of 2.2 
GBq is proposed as a good compromise to achieve the desired efficacy while reducing the 
hospital stay to 1 week. Serious adverse effects are very rare. Undesirable effects observed 
fairly frequently consist of moderate and temporary fever (29%), moderate and temporary  
disturbances of the biological liver test (20%) and hepatic pain on injection (12.5%).  
Moderate and reversible leukopenia (7%) and serious interstitial pneumopathies (2%) are 
observed more rarely 11, 12, 60. Interstitial pneumonia has been reported in an estimated 
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prevalence of 15.5 cases per 1000 treated patients with a median respiratory symptoms 
delay of 30 days61.  
Some authors have expressed their concern about hypothyroidism despite the very low 
thyroid uptake 62. Using potassium iodide premedication can significantly decrease thyroid 
iodide uptake and consequently probability of hypothyroidism 63.  
11. Conclusion 
The effectiveness of 131I-Lipiodol treatment is proven both in the treatment of HCC with 
portal thrombosis and as an adjuvant to surgery after the resection of HCCs. It is at least as 
effective as chemoembolization and is tolerated much better. Severe liver dysfunction 
represents theoretic contraindication for radioembolization as well as for TACE. In such 
cases 131I-Lipiodol is an alternative therapy option especially in tumors smaller than 6 cm.  
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